Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update


– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer –

Excerpt from:
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Related Posts